58 recruiting in this ClinicalTrials.gov snapshot · reviewed 2026-08-17
Crohn's trials specify location (ileum, colon), prior biologics, and sometimes fistula disease. Endoscopy or calprotectin thresholds often appear. Diet studies are not interchangeable with drug studies. Read the intervention type on the NCT card. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
Each headline is a rewrite of registry fields (phase, intervention, condition). Open the NCT link before you call a site. Eligibility is decided by the study team, not by this page. See how to find a trial and eligibility explained.
Phases in this snapshot: Not a traditional drug phase (23) · Phase 4 (12) · Phase 3 (11) · Phase 2 (9) · Phase 1 / Phase 2 (2) · Phase 2 / Phase 3 (1)
Intervention hubs that overlap this snapshot: Risankizumab · Adalimumab · Tirzepatide
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
NCT02421705 · Official ClinicalTrials.gov record · KU Leuven
Background: Crohn s disease (CD) is an inflammatory bowel disease. Symptoms may include diarrhea, abdominal pain, fatigue, weight loss and malnutrition.
NCT03167437 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)
This study wants to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).
NCT04372108 · Official ClinicalTrials.gov record · Janssen Scientific Affairs, LLC
The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease (CD), or other conditions for which risankizumab is an FDA-approved treatment. The registry is designed to estimate the association between risankizumab and maternal, fetal, and infant outcomes by comparing the prevalence rates of these outcomes in the exposed and unexposed populations.
NCT04846959 · Official ClinicalTrials.gov record · AbbVie
With this prospective, randomly assigned, multicentre, parallel group pragmatic non-inferiority trial, the investigators will evaluate if endoscopy-driven introduction of biological therapy is not leading to more postoperative endoscopic recurrence at week 86 compared to systematic prophylactic biological therapy in patients with CD undergoing an ileocolonic resection with ileocolonic anastomosis. Secondary analyses will include influence on clinical, biological and surgical CD recurrence, serious side effects, direct costs, work productivity, and quality of life.
NCT05169593 · Official ClinicalTrials.gov record · Universitaire Ziekenhuizen KU Leuven
This is a randomly assigned compared with a dummy treatment trial in Crohn's disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity
NCT05599347 · Official ClinicalTrials.gov record · Rambam Health Care Campus
This is a study to evaluate vedolizumab for injection (300 mg) as a safe and active treatment for Crohn's Disease in adults in China. Participants will receive an injection of Vedolizumab 300 mg at scheduled weeks 0, 2, and 6, and starting at week 14, every 8 weeks over 58 weeks or starting at week 18, every 4 weeks over 54 weeks.
NCT05837897 · Official ClinicalTrials.gov record · Takeda
This study wants to measure the clinical and endoscopic how well it works of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
NCT05923073 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
There are currently three classes of biologic treatments approved in Canada for the management of moderate-to-severe Crohn's disease: anti-tumor necrosis factor \[TNF\] alpha, anti-integrin, and anti-interleukin \[IL\]-23 targeted agents. The purpose of this trial is to determine which of these three classes of biologics results in the highest percentage of patients with small bowel (ileal) Crohn's disease entering into endoscopic remission without needing corticosteroids at 1 year.
NCT05928039 · Official ClinicalTrials.gov record · University of Calgary
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, how well it works, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies.
NCT05995353 · Official ClinicalTrials.gov record · AbbVie
Inflammatory Bowel Diseases (IBDs), including ulcerative colitis and Crohn's disease (CD), constitute a group of debilitating chronic diseases that profoundly impact patient quality of life and incurs large costs in terms of treatment and lost productivity. Incidence of IBD is rising worldwide, and there is a pressing clinical need for development of new therapies.
NCT06006039 · Official ClinicalTrials.gov record · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
This is a French prospective longitudinal watch-and-measure (no experimental treatment required) multicentre cohort study. Primary objective : to assess prospectively the presence and the extent of safety concerns (cancer, serious infections, arterial and venous thrombotic events) in patients with CD and UC and treated with JAKi, anti-IL23p19, and S1p modulators.
NCT06089590 · Official ClinicalTrials.gov record · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
A substantial fraction of IBD patients with an initial response to infliximab or adalimumab later experience re-emerging active disease despite ongoing anti-Tumour Necrosis Factor (TNF) agents maintenance therapy. The optimal intervention in patients with secondary loss-of-response (LOR) is still poorly defined, as there are still scant data on how best to choose the next intervention from among dose-intensification, switch to another anti-TNF or switch out of the anti-TNF class.
NCT06180382 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de Saint Etienne
This is a Phase 2, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, multicenter study to measure the how well it works and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
NCT06226883 · Official ClinicalTrials.gov record · Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. this study wants to measure the how well it works and safety of TAK-279 versus dummy treatment (placebo) in participants with moderately to severely active Crohn's disease (CD).
NCT06233461 · Official ClinicalTrials.gov record · Takeda
The goal of this clinical trial is to learn about the effects of fluconazole in patients who plan to start or are currently undergoing standard of care treatment and plan to dose-escalate an IL-23 therapy for their Crohn's disease. The main question it aims to assess is whether or not patient response to IL-23 therapies improve when simultaneously treated with fluconazole.
NCT06274554 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University
The purpose of this protocol is to measure the how well it works and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).
NCT06430801 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss.
NCT06548542 · Official ClinicalTrials.gov record · AbbVie
To determine if robotic surgery can be performed for inflammatory bowel disease (IBD) patients, to ascertain the optimal robotic set up for multi-quadrant IBD operations and evaluate clinical outcomes in robotic compared to laparoscopic surgery.
NCT06579443 · Official ClinicalTrials.gov record · University Hospitals Coventry and Warwickshire NHS Trust
Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission).
NCT06581328 · Official ClinicalTrials.gov record · Takeda
Crohn\'s Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD). Risankizumab is a human monoclonal antibody against IL23 p19, part of a pro-inflammatory cytokine that mediates the inflammatory response in IBD upon binding to its receptor.
NCT06606808 · Official ClinicalTrials.gov record · University Medical Center Groningen
Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC).
NCT06651281 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
This study wants to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).
NCT06663332 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
The goal of this prospective treatment study is to evaluate whether the targeted avoidance of a particular food that was diagnosed to be disruptive for the intestinal barrier during confocal laser endomicroscopy (CLE) contributes significantly to stabilizing the intestinal barrier and improving abdominal symptoms, quality of life and disease activity in Crohn's Disease patients with food-related symptoms. The main questions the study aims to answer are: * whether a food-induced intestinal barrier disorder in Crohn's disease patients can be detected by endoscopy using confocal laser endomicroscopy (CLE) and a causal relationship with certain foods can be established.
NCT06719778 · Official ClinicalTrials.gov record · Universität Duisburg-Essen
The ALPCO Calprotectin CLIA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation.
NCT06810518 · Official ClinicalTrials.gov record · American Laboratory Products Company
The main purpose of this study is to measure the how well it works and safety of mirikizumab and dummy treatment (placebo) compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
NCT06937099 · Official ClinicalTrials.gov record · Eli Lilly and Company
This is a phase 2, randomly assigned, neither you nor the study doctors know who gets the real treatment, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the how well it works of different doses of SAR442970 compared with dummy treatment (placebo) in participants with moderate to severe Crohn's disease.
NCT06958536 · Official ClinicalTrials.gov record · Sanofi
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will measure the second line effectiveness of upadacitinib and risankizumab in Crohn's Disease (CD) in a real-world setting.
NCT07073079 · Official ClinicalTrials.gov record · AbbVie
This study wants to characterize participants with Crohn's Disease (CD) and Ulcerative Colitis (UC) treated with Guselkumab in a real-world setting, and to assess the clinical effectiveness (how well the treatment works) in the overall population and in different participant subgroups. Furthermore patient-reported outcomes like fatigue, health-related quality of life (HRQoL), sexuality, work productivity and activity as well as treatment satisfaction will be assessed.
NCT07102368 · Official ClinicalTrials.gov record · Janssen-Cilag G.m.b.H
This study wants to evaluate how-well icotrokinra works (clinical how well it works) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
NCT07196722 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
The purpose of the study is to compare the clinical effectiveness and safety of newer inflammatory bowel disease (IBD) medications in anti-tumor necrosis factor (TNF) refractory patients with pediatric IBD (PIBD). Refractory means that there was no clinical response to anti-tumor necrosis factor (TNF) drugs or that the if there was a response, it is no longer present.
NCT07198113 · Official ClinicalTrials.gov record · University of North Carolina, Chapel Hill
This study wants to measure the clinical effectiveness (how well the treatment works) of Guselkumab, by lines of treatment and subpopulations, and what are the outcomes of treatment (clinical outcomes) in adult participants with moderately to severely active Ulcerative Colitis (UC) or Crohn's Disease (CD) under real-world settings. CD and UC are the main type of Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.
NCT07242248 · Official ClinicalTrials.gov record · Janssen-Cilag Ltd.
How well it works of Mirikizumab to achieve transmural healing in patients with Crohn's Disease
NCT07292012 · Official ClinicalTrials.gov record · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
This phase III, neither you nor the study doctors know who gets the real treatment, multi-center treat-through study will measure the how well it works and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).
NCT07298421 · Official ClinicalTrials.gov record · Hoffmann-La Roche
This study wants to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.
NCT07310095 · Official ClinicalTrials.gov record · Xian-Janssen Pharmaceutical Ltd.
This is a multicentre, prospective, randomly assigned, controlled, open-label study to assess the how well it works, safety, and cost-effectiveness of epigenome-guided treatment selection compared to usual standard-of-care (SOC) treatment selection in patients initiating biologic therapy for the treatment of their active Crohn's Disease (CD).
NCT07363044 · Official ClinicalTrials.gov record · Alimentiv Inc.
Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. you would be assigned to the appropriate study prior to randomization to a treatment group.
NCT07483073 · Official ClinicalTrials.gov record · Eli Lilly and Company
The main purpose of this study is to see how the safety and how well it works of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.
NCT07483099 · Official ClinicalTrials.gov record · Eli Lilly and Company
This study wants to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
NCT07499232 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
This multicenter, randomly assigned, controlled trial aims to measure the how well it works and safety of standard-dose tumor necrosis factor inhibitor (TNFi) plus low-dose upadacitinib compared with TNFi dose intensification in patients with moderate-to-severe Crohn's disease who have a suboptimal response to standard-dose TNFi therapy. Eligible participants are adults with active Crohn's disease receiving standard-dose infliximab or adalimumab who remain inadequately controlled despite ongoing treatment.
NCT07510191 · Official ClinicalTrials.gov record · Sixth Affiliated Hospital, Sun Yat-sen University
Crohn's disease (CD) is a chronic, incurable condition associated with gut inflammation. Two important treatments currently used to manage CD are special drug injections (biologics) or a liquid-only diet using specialised milkshakes.
NCT07522528 · Official ClinicalTrials.gov record · University of Glasgow
The goal of this watch-and-measure (no experimental treatment required) study is to learn about the effectiveness and safety of IL-23 inhibitors in adults with active Crohn's disease in real-world clinical practice. The main questions it aims to answer are: * What proportion of participants achieve clinical remission at Week 12 after starting treatment with an IL-23 inhibitor?
NCT07545317 · Official ClinicalTrials.gov record · Sixth Affiliated Hospital, Sun Yat-sen University
This study is a real - world clinical research of adalimumab. The project plans to enroll 30 subjects, aiming to measure the incidence of serious side effects (SAEs) within 12, 26, and 52 weeks after treatment; as well as the incidence of side effects (AEs), adverse drug reactions (ADRs), side effects of special interest (AESIs), and serious ADRs at 12, 26, and 52 weeks after treatment.
NCT07564505 · Official ClinicalTrials.gov record · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
This study wants to assess how well JNJ-78934804 works (how well it works) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).
NCT07577843 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
This study wants to evaluate how long a participant keeps taking guselkumab or continues with their treatment plan without stopping (treatment persistence) in participants with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are inflammatory bowel diseases, a group of inflammatory conditions of the colon and small intestine.
NCT07606339 · Official ClinicalTrials.gov record · Janssen-Cilag Pharma GmbH
Background: Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in the digestive tract. Symptoms include stomach pain, diarrhea, and bleeding.
NCT07619547 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
This watch-and-measure (no experimental treatment required) study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time. The study will examine whether genetic markers can help predict which patients are more likely to respond to anti-TNF therapy.
NCT07644117 · Official ClinicalTrials.gov record · Shmuel Kivity, MD
The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications. Participants can complete all study-related activities, including consent, study visits, and breast milk sample collection, from home without attending an in-person study site.
NCT07654751 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
This is a post-marketing real-world study designed to measure the how well it works and safety of Tabellvi® (Adalimumab Injection) in Chinese adult subjects with moderate to severe active Crohn's disease via a single-arm trial. A total of 50 subjects are planned to be enrolled.
NCT07663526 · Official ClinicalTrials.gov record · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
This retrospective cohort study aims to compare the how well it works of different biologics in preventing postoperative endoscopic recurrence in Crohn's disease (CD). It plans to include 198 adult patients who underwent bowel resection and initiated prophylactic biologic therapy between January 1, 2015, and April 1, 2025.
NCT07694674 · Official ClinicalTrials.gov record · Shanghai 10th People's Hospital
Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain, diarrhea, tiredness, and weight loss.
NCT07697456 · Official ClinicalTrials.gov record · AbbVie
Background: Irritable Bowel Syndrome (IBS) affects approximately 4.1% of the global population and imposes a significant personal and healthcare burden. Recent evidence highlights the role of low-grade inflammation, impaired intestinal permeability and gut microbiota dysbiosis in the pathophysiology of non-constipated IBS (IBS with predominate diarrhea; IBS-D and mixed type IBS; IBS-M).
NCT07707635 · Official ClinicalTrials.gov record · Ariel University
Inflammatory Bowel Disease (IBD) patients have an increased risk of ColoRectal Cancer (CRC). The cumulative risk of CRC development is estimated at 1% after 10 years of disease progression, 2% after 20 years, and 5% after more than 20 years of disease progression (1).
NCT07719426 · Official ClinicalTrials.gov record · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
The primary purpose of this study is to measure the how well it works of SL-325 in adult participants with moderate to severely active Crohn's disease. The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.
NCT07753850 · Official ClinicalTrials.gov record · Shattuck Labs, Inc.
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is a chronic relapsing intestinal disorder driven by immune dysregulation, impaired mucosal barrier function, and gut microbiome dysbiosis. Although current therapies can control inflammation, many patients still experience recurrent symptoms, treatment resistance, adverse effects, and impaired quality of life.
NCT07799428 · Official ClinicalTrials.gov record · Anabio R&D
Crohn's disease is an inflammatory bowel disease characterized by relapses and remissions, causing lesions throughout the digestive tract and accompanied by diarrhea, abdominal pain, and nutritional disorders. In Japan particularly, the incidence of anal lesions is high, with approximately half of patients developing fistulas or abscesses, significantly impairing quality of life (QOL).
NCT07872449 · Official ClinicalTrials.gov record · Yuki Horio
IBD pregnancy requires multidisciplinary management, but access to this may be difficult for some, resulting in variation in care which may in turn impair quality of healthcare delivery. We need to devise innovative ways to deliver care to overcome these barriers.
NCT07916727 · Official ClinicalTrials.gov record · Austin Health
Children and young adults with Crohn's disease may develop iron deficiency anemia, a condition in which low iron levels reduce the number of healthy red blood cells. This study aims to develop and test a model to help identify which iron treatment approached are most effective for these patients.
NCT07925450 · Official ClinicalTrials.gov record · Weill Medical College of Cornell University
This hub lists 58 recruiting Crohn's disease studies from a ClinicalTrials.gov snapshot, rewritten in plain English. Each card links to its NCT record. You can also search the official registry for “Crohn disease” at https://clinicaltrials.gov/search?cond=Crohn%20disease.
A phase explainer, a plain-English summary grounded in the brief summary, inclusion/exclusion extracted from the public eligibility block, sponsor name, and any central contact the sponsor published. It is not a match to a trial.
Sites that appear on these records include Budapest, Hungary; Warsaw, Poland; New York, New York; Seoul, South Korea; London, United Kingdom. A city on a record is not a guarantee that the site is taking new patients this week — call the NCT contact.
No. Eligibility is decided by the study team using the protocol, labs, and consent. Our “who it is for” list is a readable extract of public inclusion text only.
Biologics, JAK inhibitors, and tapering studies for people already on treatment.
B-cell and interferon-pathway drugs for SLE and lupus nephritis.
Injectable biologics, oral TYK2 drugs, and combination skin studies.
Gut-targeted biologics, oral small molecules, and combination induction studies.
Knee and hip pain studies, injections, devices, and exercise programs.
Biologics, JAK inhibitors, and topical studies for eczema.